Can I Take Rhodiola with Zetia (Ezetimibe)?

What Is Ezetimibe and How Does It Work?

Ezetimibe selectively blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush-border, reducing cholesterol absorption by roughly 50% [1]. After a 10 mg oral dose, ezetimibe is glucuronidated in the intestinal wall and liver primarily through UGT1A1 and UGT1A3 enzymes, not through CYP3A4 or CYP2C8 to any meaningful clinical degree [2]. That metabolic pathway matters when assessing supplement interactions: most herbal interactions occur at CYP enzymes, so ezetimibe carries a lower baseline risk than statins for herb-drug collisions.

Efficacy Snapshot

In the IMPROVE-IT trial (N=18,144), adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL-C by an additional 23.6% compared with simvastatin alone, translating to a 6.4% relative reduction in major cardiovascular events over 6 years (P<0.001) [3]. The FDA approved ezetimibe in 2002; the current label specifies that the drug is indicated as adjunct therapy to diet in adults with primary hyperlipidemia [4].

Common Adverse Effects

The most reported adverse effects are upper respiratory infections (4.3%) and diarrhea (4.1%) based on pooled clinical trial data cited in the FDA label [4]. Myopathy and hepatotoxicity are rare when ezetimibe is used as monotherapy, though the risk rises modestly when it is combined with a statin [3].

What Is Rhodiola Rosea?

Rhodiola rosea is a flowering plant in the Crassulaceae family, native to arctic and mountainous regions of Europe and Asia. It is sold as an adaptogen, most commonly as a root extract standardized to 3% rosavins and 1% salidroside [5]. Typical study doses range from 200 mg to 680 mg per day.

Active Constituents and Proposed Mechanisms

The primary bioactive compounds are rosavins (rosavin, rosin, rosarin) and salidroside (p-tyrosol glucoside). Salidroside has demonstrated inhibition of monoamine oxidase A (MAO-A) and MAO-B activity in preclinical models, which produces mild serotonin and dopamine modulation [6]. A 2012 in vitro study published in Phytomedicine identified dose-dependent MAO inhibition by salidroside extracts (IC50 for MAO-A approximately 0.37 mg/mL), raising the theoretical concern of serotonergic additive effects when combined with serotonergic drugs [6].

Adaptogenic Evidence

The evidence base for rhodiola as a stress and fatigue adaptogen is modest but growing. A randomized controlled trial by Spasov et al. (N=56 students) found rhodiola SHR-5 extract 50 mg twice daily significantly reduced fatigue scores versus placebo over 20 days (P<0.05) [7]. A 2012 Cochrane-style systematic review by Hung et al. Identified 11 RCTs of rhodiola for physical and mental fatigue, concluding that evidence was promising but methodologically limited [8]. Rhodiola does not appear in the ACC/AHA 2019 Primary Prevention Guideline as having any documented lipid-lowering effect [9].

Does Rhodiola Affect CYP Enzymes Relevant to Ezetimibe?

This is the most mechanistically relevant question. Ezetimibe's glucuronidation pathway (UGT1A1/UGT1A3) is largely separate from CYP450, so herbal CYP modulation has a reduced direct impact on ezetimibe plasma levels [2].

CYP3A4 and CYP2C9 Data for Rhodiola

A 2008 study by Panossian et al. In Phytomedicine tested rhodiola extract SHR-5 on a panel of CYP enzymes in human liver microsomes [10]. The extract showed weak inhibition of CYP3A4 at concentrations exceeding typical oral doses, but the inhibition was not considered clinically meaningful at standard supplement dosing [10]. No rhodiola constituent has been shown to induce CYP enzymes significantly in clinical pharmacokinetic studies.

UGT1A1 and Rhodiola

Direct studies on rhodiola's effect on UGT1A1 or UGT1A3 activity are absent from the published literature as of January 2025. Given that ezetimibe clearance depends on these glucuronosyltransferases, the lack of data does not confirm safety but also provides no signal of concern [2].

P-glycoprotein Considerations

Ezetimibe is a substrate of P-glycoprotein (P-gp) efflux transporters [4]. Rhodiola constituents have not been identified as clinically significant P-gp inhibitors or inducers in human studies, though in vitro screening has suggested weak P-gp interaction at high salidroside concentrations [11].

Serotonergic and Pharmacodynamic Interaction Risk

The pharmacodynamic concern is more clinically relevant than the pharmacokinetic one, particularly for patients already taking serotonergic medications alongside ezetimibe.

MAO Inhibition by Rhodioda Constituents

As noted above, salidroside demonstrates MAO-A and MAO-B inhibition in vitro [6]. MAO-A inhibition raises serotonin and norepinephrine levels. If a patient is simultaneously taking an SSRI (e.g., sertraline 50 mg), an SNRI (e.g., duloxetine 60 mg), or tramadol, adding rhodiola could theoretically contribute to serotonin syndrome. This concern is not unique to the ezetimibe combination; it applies to any co-administration of rhodiola with serotonergic drugs [12].

Ezetimibe Has No Serotonergic Activity

Ezetimibe itself has no known serotonergic, dopaminergic, or monoaminergic pharmacology [4]. The serotonin risk from taking rhodiola with Zetia alone, in the absence of other serotonergic drugs, is minimal.

Cardiovascular Pharmacodynamic Effects

Rhodiola has shown mild cardioprotective effects in animal models, including reduced ischemia-reperfusion injury, partly through Nrf2 activation and antioxidant pathways [13]. No human RCT has documented rhodiola reducing LDL-C, triglycerides, or cardiovascular events. Adding rhodiola to ezetimibe therapy would not be expected to meaningfully change lipid panel results [9].

Practical Dosing and Timing Guidance

No pharmacokinetic data support a required dose-separation window between rhodiola and ezetimibe. The following framework reflects current understanding of each agent's absorption kinetics.

Ezetimibe Absorption Timeline

Ezetimibe reaches peak plasma concentration (Tmax) in 1 to 2 hours after oral dosing and has a half-life of approximately 22 hours for the active ezetimibe-glucuronide metabolite [4]. It may be taken with or without food, at any time of day, though consistent daily timing improves adherence.

Rhodiola Absorption Timeline

Salidroside reaches Tmax in approximately 0.5 to 1 hour in rodent pharmacokinetic studies; human Tmax data are sparse but suggest rapid absorption [14]. Rhodiola is commonly taken in the morning or early afternoon because its mild stimulant properties may interfere with sleep if taken in the evening.

Suggested Approach

Taking ezetimibe at a consistent time (morning or evening, per patient preference) and rhodiola in the morning or at breakfast is a workable regimen. No data support mandatory separation. If GI side effects occur from either agent, taking them with food reduces discomfort, since ezetimibe's absorption is unaffected by food [4].

Who Should Exercise Extra Caution?

Several patient profiles warrant a conversation with their prescriber before combining rhodiola and ezetimibe.

Patients on Serotonergic Drugs

Any patient taking SSRIs, SNRIs, tricyclic antidepressants, buspirone, lithium, triptans, or opioids with serotonergic activity (tramadol, meperidine) should discuss rhodiola with their physician before use. The MAO-inhibitory properties of salidroside create a plausible, if unquantified, additive serotonergic risk [6, 12].

Patients with Bipolar Disorder

Rhodiola's mild stimulant and MAO-inhibitory effects may theoretically destabilize mood in patients with bipolar disorder [12]. This concern is independent of ezetimibe.

Patients with Liver Disease

Both ezetimibe and rhodiola are hepatically processed. Ezetimibe is generally avoided in moderate-to-severe hepatic impairment per FDA labeling [4]. Patients with Child-Pugh B or C liver disease should not add an additional hepatically metabolized supplement without specialist guidance.

Pregnant and Breastfeeding Patients

Ezetimibe is FDA Pregnancy Category X when used as part of statin combination therapy; its safety in pregnancy as monotherapy is not established [4]. Rhodiola has no adequate human pregnancy safety data [5]. Neither should be used during pregnancy without a physician's direction.

Monitoring Parameters After Starting the Combination

Once a patient is stable on ezetimibe and decides to add rhodiola (after prescriber clearance), the following monitoring schedule is appropriate.

Lipid Panel

Recheck a fasting lipid panel 6 to 8 weeks after starting or changing any lipid-lowering agent, per ACC/AHA 2019 guidelines [9]. Rhodiola does not affect LDL-C, so no change in lipid trajectory is expected from adding the supplement.

Hepatic Function

Routine LFT monitoring is not required for ezetimibe monotherapy in patients without pre-existing liver disease, per the FDA label [4]. Adding rhodiola does not change this recommendation, but any new onset of jaundice, right upper quadrant pain, or dark urine warrants prompt evaluation.

Symptom Monitoring

Patients should watch for and report:

• New or worsening GI symptoms (nausea, diarrhea, abdominal pain)
• Agitation, restlessness, tremor, or rapid heart rate (possible serotonergic symptoms)
• Unusual fatigue or muscle pain (myopathy signal, especially if ezetimibe is co-prescribed with a statin)

A 2022 case series in the Journal of Clinical Pharmacy and Therapeutics described three patients with serotonin-like symptoms after adding rhodiola to existing SSRI regimens, reinforcing the importance of screening for concurrent serotonergic drug use before recommending the supplement [12].

What Do Clinical Guidelines Say About Supplement Combinations with Ezetimibe?

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "Clinicians should routinely assess patient use of dietary supplements because of potential interactions with cardiovascular medications" [9]. The guideline does not name rhodiola specifically but places the burden on clinicians to investigate supplement co-administration.

The European Atherosclerosis Society 2019 Consensus Statement on LDL-C lowering does not list any herb-ezetimibe interactions but recommends that patients on LDL-lowering therapy avoid supplements with unverified lipid effects that could confound monitoring [15].

Natural Medicines Database (Therapeutic Research Center) classifies the rhodiola-ezetimibe combination as "unknown" interaction severity, meaning insufficient evidence exists to confirm either safety or risk, a classification that reflects the absence of clinical trial data rather than confirmed harm [5].

The American Heart Association's 2023 Supplement and Heart Health advisory states that "no dietary supplement has been shown to replace guideline-directed lipid-lowering therapy," reinforcing that rhodiola should not be used as a substitute for ezetimibe or statins in patients with established cardiovascular risk [16].

Key Takeaways for Patients and Clinicians

Ezetimibe and rhodiola rosea do not share a documented clinically significant drug-herb interaction in the peer-reviewed literature as of January 2025. The metabolic mismatch between ezetimibe's UGT-based glucuronidation and rhodiola's mild CYP3A4 effects reduces pharmacokinetic collision risk [2, 10]. The more relevant clinical consideration is rhodiola's serotonergic pharmacodynamics, which matter most when other serotonergic drugs are present in the patient's regimen [6, 12].

Clinicians evaluating a patient on ezetimibe 10 mg who wants to add rhodiola 200 to 400 mg daily should screen for concurrent serotonergic medications, confirm the patient has no significant hepatic impairment, and recheck the lipid panel at the next scheduled interval. No dose-separation window is required based on current evidence.

If you are already taking both and have not experienced adverse effects after 4 to 8 weeks, continue your normal regimen and report any new GI, mood, or musculoskeletal symptoms at your next appointment. Schedule a fasting lipid panel at the 6-to-8-week mark after any change to your regimen per ACC/AHA 2019 guidance [9].